FDA approves Pepaxto
Oncopeptides’ Pepaxto has been approved for patients with triple-class refractory multiple myeloma
approvals
FDA approves Libtayo for basal cell carcinoma
Libtayo receives full approval in locally advanced BCC and accelerated approval in metastatic BCC
FDA approves new treatment for NSCLC
FDA approves Tepmetko as a once-daily oral MET inhibitor for NSCLC with METex14 skipping alterations
Additional EU approvals for RINVOQ
The European Commission has approved AbbVie’s RINVOQ (upadacitinib) for treatment of psoriatic arthritis and ankylosing spondylitis
BNT162b2 becomes first authorized COVID-19 vaccine
Pfizer and BioNTech have achieved the first authorization for a vaccine against COVID-19
